MedTrace Logo

Efficacy of SN132D in Patients With Suspected Endometriosis

NCT05664828 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-12-12

No results posted yet for this study

Summary

This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.

Conditions

  • Endometriosis

Interventions

DRUG

SN132D

Manganese-based macromolecular MRI contrast agent

Sponsors & Collaborators

  • Spago Nanomedical AB

    lead INDUSTRY

Principal Investigators

  • Ligita Jokubkiene, MD, PhD · Senior Consultant Skåne University Hospital, Assoc Prof Lund University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-17
Primary Completion
2023-06-20
Completion
2023-09-12

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05664828 on ClinicalTrials.gov